{"product_id":"vrpx-vrio-analysis","title":"Virpax Pharmaceuticals, Inc. (VRPX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the secret sauce behind Virpax Pharmaceuticals, Inc. (VRPX)'s market position. This VRIO analysis distills whether their core assets are truly Valuable, Rare, Inimitable, and Organized (\u0026amp;O4\u0026amp;), offering a sharp, immediate verdict on their sustainable competitive advantage. Read on to see exactly what sets them apart - or where their vulnerabilities lie.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Proprietary Drug Delivery Platforms (e.g., Liposomal Encapsulation)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at the core engine of Virpax Pharmaceuticals, Inc.’s value proposition: their drug delivery technology. Honestly, in biotech, the molecule is only half the battle; getting it where it needs to go, and keeping it there, is the real trick. These platforms - liposomal encapsulation for Probudur™ and Molecular Envelope Technology (MET) for Envelta™ - are what set them apart from just another drug developer.\u003c\/p\u003e\n\n\u003cp\u003eThe platform’s value is clear in the pipeline. Probudur™, their long-acting liposomal bupivacaine, has preclinical data suggesting pain control for up to \u003cstrong\u003e96 hours\u003c\/strong\u003e, which is a massive compliance and efficacy boost over standard treatments. Envelta™ uses MET to deliver enkephalin intranasally, aiming to bypass the blood-brain barrier for CNS targets. This focus on novel, targeted delivery for pain and CNS disorders is where the real potential lies.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Novel Formulations and Efficacy Targets\u003c\/h3\u003e\n\u003cp\u003eThe liposomal encapsulation allows for sustained-release formulations like Probudur™, designed to manage post-operative pain over an extended period. This directly addresses the market need for non-opioid, long-duration pain relief, a multi-billion dollar space. The technology is designed to improve patient compliance because fewer doses are needed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProbudur™ aims for pain control up to \u003cstrong\u003e96 hours\u003c\/strong\u003e post-injection.\u003c\/li\u003e\n\u003cli\u003eEnvelta™ targets CNS delivery via the nose, potentially reducing drug-to-drug interaction.\u003c\/li\u003e\n\u003cli\u003eThe platforms support both prescription and over-the-counter candidates.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: Patented Technology and Development Milestones\u003c\/h3\u003e\n\u003cp\u003eSpecialized, patented delivery systems that are actively moving toward regulatory review are rare finds. Virpax is developing two distinct patented platforms. The fact that Probudur™ has shown positive results in a dose range finding study and is moving toward Investigational New Drug (IND) application steps as of March 2025 signals tangible progress beyond mere concept.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is the dependency on the licensed MET platform for Envelta™; while Virpax has rights, the core IP originates elsewhere. Still, the combination and application to their specific drug candidates are unique to them.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Scientific Depth and Patent Moats\u003c\/h3\u003e\n\u003cp\u003eReplicating these platforms isn't a weekend project. It demands deep, specialized scientific expertise in nanotechnology and lipid formulation, which takes years to build. Competitors face a high barrier to entry due to the existing patent protection around Probudur™ and the licensed MET technology.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eImitability Factor\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific Expertise\u003c\/td\u003e\n\u003ctd\u003eHigh Barrier\u003c\/td\u003e\n\u003ctd\u003eRequires deep knowledge in liposomal encapsulation and nanotechnology.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Protection\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eProvisional patent applications filed for key candidates like Envelta™.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime\/Cost to Replicate\u003c\/td\u003e\n\u003ctd\u003eSignificant\u003c\/td\u003e\n\u003ctd\u003eCompetitors face lengthy R\u0026amp;D cycles to achieve similar preclinical validation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization: Capital Deployment for Exploitation\u003c\/h3\u003e\n\u003cp\u003eThe company has shown intent to exploit these assets by securing necessary capital. Virpax Pharmaceuticals closed a public offering of \u003cstrong\u003e$\\text{\\$6.0}$ million\u003c\/strong\u003e in January 2025, with proceeds specifically earmarked to fund development activities, including commencing the clinical trial for Probudur™. This capital infusion demonstrates the organization is structured to push these proprietary assets through critical milestones, like the IND filing.\u003c\/p\u003e\n\u003cp\u003eTo be fair, the company’s overall financial health, evidenced by a low current ratio of \u003cstrong\u003e0.13\u003c\/strong\u003e and a small market cap of just \u003cstrong\u003e$\\text{\\$1.36}$ million\u003c\/strong\u003e as of late January 2025, suggests moderate organizational capacity to sustain long-term, high-cost development without further financing.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Path to Sustained Edge\u003c\/h3\u003e\n\u003cp\u003eThe advantage here is not guaranteed, but the potential is significant. If the patents remain robust and Probudur™ or Envelta™ successfully navigate clinical trials, validating the superior efficacy over current standards of care, this platform provides a \u003cstrong\u003esustained competitive advantage\u003c\/strong\u003e. If clinical hurdles or patent challenges arise, the advantage reverts to temporary.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e if IND\/Phase 1 fails.\u003c\/li\u003e\n\u003cli\u003eAdvantage is \u003cstrong\u003eSustained\u003c\/strong\u003e if patents hold and clinical superiority is proven.\u003c\/li\u003e\n\u003cli\u003eThe goal is to displace existing long-acting anesthetics like EXPAREL®.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Probudur Injectable Anesthetic Development Status\n\u003c\/h2\u003e\n\u003cp\u003eProbudur Injectable Anesthetic Development Status\u003c\/p\u003e\n\u003cp\u003eValue: Represents a near-term potential asset, having shown positive results in a dose range study moving toward an Investigational New Drug (IND) filing as of March 2025.\u003c\/p\u003e\n\u003cp\u003eRarity: Moderate; many companies have late-stage pain candidates, but a non-opioid, long-acting injectable is a specific, valuable niche.\u003c\/p\u003e\n\u003cp\u003eImitability: Difficult; the specific formulation and positive trial data are unique to Virpax Pharmaceuticals' process.\u003c\/p\u003e\n\u003cp\u003eOrganization: Moderate; the company explicitly earmarked recent offering proceeds to fund its commencement toward clinical trials.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary; advantage is temporary until IND is approved and Phase 1 data is secured.\u003c\/p\u003e\n\u003cp\u003eThe development progress is supported by recent financing activities and preclinical performance metrics.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancing Event\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eStated Purpose Related to Probudur\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Offering Closing (Jan 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFund clinical trial development for Probudur.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Offering Closing (Nov 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFund ongoing activities in connection with planned Investigational New Drug (IND) filing for Probudur.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrant Exercise Proceeds\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$2.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGeneral corporate purposes, following earlier financing activity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company underwent a \u003cstrong\u003e1-for-25\u003c\/strong\u003e reverse stock split effective March 20, 2025, reducing outstanding shares from approximately \u003cstrong\u003e31,062,581\u003c\/strong\u003e to \u003cstrong\u003e1,242,504\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003ePreclinical data supporting the potential value and rarity include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePositive results from a beagle dog dose range finding (DRF) study announced March 18, 2025, as an important step towards IND application.\u003c\/li\u003e\n\u003cli\u003ePreclinical studies showing long duration pain control for at least \u003cstrong\u003e96 hours\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA rat incisional model demonstrating analgesia for up to \u003cstrong\u003efive (5) days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn vitro studies demonstrating a slow release of bupivacaine that lasted for up to \u003cstrong\u003esix (6) days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eComparison studies in rat incision models demonstrating efficacy \u003cstrong\u003ethree times longer\u003c\/strong\u003e than Exparel at doses of \u003cstrong\u003e3 mg\u003c\/strong\u003e and \u003cstrong\u003e6 mg\u003c\/strong\u003e, or \u003cstrong\u003efour to five times longer\u003c\/strong\u003e effect with different formulations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Molecular Envelope Technology (MET) Platform\n\u003c\/h2\u003e\n\n\u003ch\u003eMolecular Envelope Technology (MET) Platform\u003c\/h\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Versatile platform being explored for intranasal vaccines (like a COVID vaccine application mentioned in March 2025), opening potential non-pain markets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; novel delivery tech applicable across different therapeutic areas is not common, especially with government interest.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires reverse-engineering the specific MET process and associated know-how.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; they have an agreement with the U.S. Department of Health and Human Services for NES100 development using this tech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if MET proves broadly applicable and superior for vaccine delivery, this is a long-term differentiator.\u003c\/p\u003e\n\n\u003cp\u003eThe MET platform underpins several product candidates, demonstrating its broad applicability:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNES100: Intranasal enkephalin for acute and chronic non-cancer pain.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eNobrXiol™: Nasal delivery of pharmaceutical-grade cannabidiol (CBD) for rare pediatric epilepsy.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eExploration for Intranasal mRNA COVID Vaccine.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eKey organizational and financial context related to the platform's development:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Agreement\u003c\/th\u003e\n\u003cth\u003eDetail\/Amount\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHHS\/NCATS Agreement\u003c\/td\u003e\n\u003ctd\u003eExtension of cooperative R\u0026amp;D agreement for NES100 development.\u003c\/td\u003e\n\u003ctd\u003eOngoing\/Extended (Mentioned Nov 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic Offering\u003c\/td\u003e\n\u003ctd\u003eClosing of $6.0 million in common stock and pre-funded warrants.\u003c\/td\u003e\n\u003ctd\u003eJanuary 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Performance Context\u003c\/td\u003e\n\u003ctd\u003eStock surged 86.5% in premarket following NES100 extension news.\u003c\/td\u003e\n\u003ctd\u003eNovember 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock Price (Recent)\u003c\/td\u003e\n\u003ctd\u003e$0.021\u003c\/td\u003e\n\u003ctd\u003eAs of December 5, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReverse Stock Split\u003c\/td\u003e\n\u003ctd\u003e1-for-25 split, reducing shares from approx. 31,062,581 to 1,242,504.\u003c\/td\u003e\n\u003ctd\u003eEffective March 20, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e$3.2 million (up from $1.5 million in Q1 2023).\u003c\/td\u003e\n\u003ctd\u003ePeriod ended March 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Reserves\u003c\/td\u003e\n\u003ctd\u003eApproximately $1.9 million.\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe MET platform's development is supported by collaborations beyond the HHS agreement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eCompetitive cooperative research and development agreements (CRADAs) for two prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Government Grant Acquisition Competency\n\u003c\/h2\u003e\n\u003cp\u003e\nThe competency in Government Grant Acquisition is assessed based on the VRIO framework:\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment Detail\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eProvides non-dilutive funding, preserving cash runway.\u003c\/td\u003e\n\u003ctd\u003eCritical given the negative \u003cstrong\u003e12,067\u003c\/strong\u003e Thousand USD net income for the trailing twelve months ending December 2024. Total Assets were \u003cstrong\u003e1,556\u003c\/strong\u003e Thousand USD as of December 31, 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate; core competency in successfully winning competitive grants.\u003c\/td\u003e\n\u003ctd\u003eSuccessful pursuit includes an in-kind grant from the National Center for Advancing Translational Sciences (NCATS) for Envelta.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult; success is tied to specific scientific merit and agency relationships.\u003c\/td\u003e\n\u003ctd\u003eThe NCATS CRADA supports Envelta development, with related contracts, such as one for \u003cstrong\u003e$1.87 million\u003c\/strong\u003e with Recro Pharma in October 2021, demonstrating tangible support.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eHigh; actively pursued as an excellent source of capital.\u003c\/td\u003e\n\u003ctd\u003eThe company views this strategy as an excellent source of non-dilutive funding. The company closed a public offering of \u003cstrong\u003e$6.0 million\u003c\/strong\u003e in January 2025, highlighting the need for non-dilutive alternatives.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary; sustained only as long as they can keep winning competitive grants.\u003c\/td\u003e\n\u003ctd\u003eContinued success depends on the ongoing ability to secure future awards against other applicants.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nFurther context on the grant-supported development:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nEnvelta (MET-LENK) is funded under an in-kind grant from NCATS, part of the NIH.\n\u003c\/li\u003e\n\u003cli\u003e\nThe NIH\/NCATS CRADA, entered into in August 2020, supports IND-enabling studies for Envelta.\n\u003c\/li\u003e\n\u003cli\u003e\nNCATS awarded contracts to support Good Manufacturing Practices (GMP) production and Good Laboratory Practices (GLP) toxicology for Envelta.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Zero Total Debt Position (as of Dec 31, 2024)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eZero Total Debt Position (as of Dec 31, 2024)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProvides maximum financial flexibility and reduces immediate solvency risk, especially important for a preclinical firm with \u003cstrong\u003e0\u003c\/strong\u003e USD in total debt. The company reported \u003cstrong\u003e$0.0\u003c\/strong\u003e in total debt.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; many preclinical firms carry debt, but zero debt is a strong, clean balance sheet feature. The debt-to-equity ratio is reported as \u003cstrong\u003e0%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eEasy; any company can choose to fund operations purely through equity or grants to avoid debt.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; the company has clearly opted for an equity\/grant-focused financing strategy.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; this advantage erodes quickly if significant debt is taken on for late-stage trials or if equity financing becomes too dilutive.\u003c\/p\u003e\n\u003cp\u003eThe financial structure supporting this position is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eVirpax Pharmaceuticals (VRPX) Value\u003c\/td\u003e\n\u003ctd\u003eContext\/Reference Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt to Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.56 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-US$913.8K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, US$\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.51m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe financing strategy is evidenced by recent capital activities and balance sheet composition:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company has a total debt of \u003cstrong\u003e$0.0\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe debt-to-equity ratio is \u003cstrong\u003e0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal assets were reported at \u003cstrong\u003e$1.56 million\u003c\/strong\u003e in the latest quarter.\u003c\/li\u003e\n\u003cli\u003eTotal liabilities were reported at \u003cstrong\u003e$2.47 million\u003c\/strong\u003e in the latest quarter.\u003c\/li\u003e\n\u003cli\u003eShareholder equity is negative at \u003cstrong\u003e-US$913.8K\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Envelta Intranasal CNS Delivery Candidate\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Targets the high-value, high-difficulty CNS market with a nanotechnology-based spray for brain delivery of peptides, addressing significant unmet needs in acute and chronic pain management, including cancer pain, by targeting delta opioid receptors and avoiding mu receptor side effects.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; direct, non-invasive brain delivery of peptides via the olfactory route, bypassing the blood-brain barrier, is a significant hurdle in CNS drug development.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very Difficult; this involves the proprietary Molecular Envelope Technology (MET) licensed from Nanomerics Ltd., which creates stable nanoparticles to encapsulate and protect the enkephalin peptide (MET-LENK).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; progress is being made toward an Investigational New Drug (IND) filing, supported by an in-kind grant from the National Center for Advancing Translational Sciences (NCATS) at the NIH, awarded on \u003cstrong\u003e8\/31\/2020\u003c\/strong\u003e. The Company expected to submit the IND in \u003cstrong\u003emid-2024\u003c\/strong\u003e or later in \u003cstrong\u003e2024\u003c\/strong\u003e following FDA Pre-IND review. Research and development expenses for the year ended December 31, 2023, were $\u003cstrong\u003e5.1 million\u003c\/strong\u003e. Cash as of December 31, 2023, was approximately $\u003cstrong\u003e9.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if successful, this platform could command premium licensing deals and market positioning as a non-addictive alternative for severe pain.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Data Point\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Efficacy (Animal)\u003c\/td\u003e\n\u003ctd\u003eDose-Response Noted in CFA Anti-Hyperalgesia Model\u003c\/td\u003e\n\u003ctd\u003eDose-response noted vs. placebo and subcutaneous morphine\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Efficacy (Animal)\u003c\/td\u003e\n\u003ctd\u003eHigh-Dose MET-LENK Administration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e30 mg\/kg\u003c\/strong\u003e significantly decreased hypersensitivity in treated animals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical Safety (Animal)\u003c\/td\u003e\n\u003ctd\u003e14-Day Rat Dose Range Finding Study (DRF) Findings\u003c\/td\u003e\n\u003ctd\u003eNo treatment related clinical signs or mortality; no related findings in hematology, coagulation, and serum chemistry data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Context (R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003eResearch and Development Expenses (Year Ended 12\/31\/2023)\u003c\/td\u003e\n\u003ctd\u003e$\u003cstrong\u003e5.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Context (Cash Position)\u003c\/td\u003e\n\u003ctd\u003eCash Balance as of December 31, 2023\u003c\/td\u003e\n\u003ctd\u003eApproximately $\u003cstrong\u003e9.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Context (Operating Loss)\u003c\/td\u003e\n\u003ctd\u003eOperating Loss (Year Ended 12\/31\/2023)\u003c\/td\u003e\n\u003ctd\u003e$\u003cstrong\u003e15.2 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe development is supported by a Cooperative Research and Development Agreement (CRADA) with NCATS, which has also supported Good Manufacturing Practices (GMP) production and GLP toxicology studies.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eEnvelta is also being considered for a second indication, PES200, for post-traumatic stress disorder (PTSD).\u003c\/li\u003e\n\u003cli\u003eThe MET intranasal delivery formulation has been determined to bypass the liver, avoiding potential drug-to-drug interactions.\u003c\/li\u003e\n\u003cli\u003eThe Company's operating loss for the year ended December 31, 2022, was $\u003cstrong\u003e21.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash used in operations for the year ended December 31, 2022, was $\u003cstrong\u003e17,846,708\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Epoladerm Topical NSAID Asset\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eEpoladerm Topical NSAID Asset\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Offers a differentiated, non-opioid topical treatment for osteoarthritis (OA), a massive chronic pain market with high patient demand for alternatives.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMarket Metric\u003c\/th\u003e\n\u003cth\u003eValue\/Statistic\u003c\/th\u003e\n\u003cth\u003eYear\/Period\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Osteoarthritis Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 9.34 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eProjected to reach USD 21.22 billion by 2034 (CAGR of 8.6%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal NSAIDs Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 15.58 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2019\u003c\/td\u003e\n\u003ctd\u003eProjected to reach USD 32.33 billion by 2032 (CAGR of 5.8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKnee Osteoarthritis Drugs Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUSD 6.7 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eProjected to reach USD 14.3 billion by 2034 (CAGR of 8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNSAIDs Osteoarthritis Therapeutics Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$ 2164.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eEstimated CAGR of 6% from 2024 to 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Adults with OA Prevalence\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1 in 5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCurrent estimate\u003c\/td\u003e\n\u003ctd\u003eAmong adults 60 years and older, symptomatic knee OA prevalence is approximately 10% in men and 13% of women\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; topical pain treatments are common, but a novel, effective NSAID delivery system is less so.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClinical practice guidelines from the American Academy of Family Physicians and the American College of Physicians recommend topical non-steroidal anti-inflammatory drugs (NSAIDs) as first-line therapy before recommending oral NSAIDs.\u003c\/li\u003e\n\u003cli\u003eThe anti-inflammatory segment dominated the topical NSAIDs market revenue share at \u003cstrong\u003e38.6%\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate; while the concept is known, the specific formulation and delivery mechanism are protected.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEpoladerm is a diclofenac topical spray film formulation.\u003c\/li\u003e\n\u003cli\u003eVirpax announced filing a new provisional patent application entitled “NSAID Formulation and Method” related to Epoladerm in \u003cstrong\u003eAugust 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Moderate; it is part of the core pipeline being advanced, though less frequently highlighted than Probudur in recent 2025 updates.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVirpax executed a clinical trial agreement for a first-in-human pilot study in Canada in \u003cstrong\u003eDecember 2021\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company completed all FDA-required pre-clinical studies for Epoladerm, including dermal toxicity, sensitization, irritation, phototoxicity, and PK characteristics.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the year ended \u003cstrong\u003eDecember 31, 2023\u003c\/strong\u003e, were \u003cstrong\u003e$5.1 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the three months ended \u003cstrong\u003eMarch 31, 2024\u003c\/strong\u003e, the operating loss was \u003cstrong\u003e$3.2 million\u003c\/strong\u003e, and cash and cash equivalents were approximately \u003cstrong\u003e$1.9 million\u003c\/strong\u003e at \u003cstrong\u003eMarch 31, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; advantage is tied to achieving clinical proof-of-concept superior to existing topical options.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Integrated Discovery-to-cGMP Manufacturing Model\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003ePotentially streamlines development, reduces reliance on external Contract Manufacturing Organizations (CMOs), and allows for tighter quality control over proprietary formulations. The company's strategy is supported by non-dilutive funding through government grants, such as those awarded by the National Center for Advancing Translational Sciences (NCATS) to support Good Manufacturing Practices (GMP) production of drug substance and drug product for Envelta™.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eFor a small, preclinical company, having this capability in-house is unusual and suggests specialized infrastructure. The company's operational scale is indicated by its reported employee count of approximately $\\text{7}$ employees as of recent market data.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eBuilding cGMP (current Good Manufacturing Practice) facilities and the associated quality systems is a multi-million dollar, multi-year undertaking. The scale of this investment is contextualized by the Company's financial position as of December 31, 2023, which included cash of approximately $\\text{\\$9.1}$ million. The operating loss for the year ended December 31, 2023, was $\\text{\\$15.2}$ million.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss\u003c\/td\u003e\n\u003ctd\u003e$\\text{-}\\mathbf{\\$15.2}$ million\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance\u003c\/td\u003e\n\u003ctd\u003e$\\text{Approximately } \\mathbf{\\$9.1}$ million\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{1.24}$ million\u003c\/td\u003e\n\u003ctd\u003eRecent Market Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{\\$2.57}$M\u003c\/td\u003e\n\u003ctd\u003eAs of March 21, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThis capability is cited as a bullish factor, implying the structure is in place to support pipeline progression. Ownership structure details include:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eInstitutional Ownership: $\\mathbf{32.23\\%}$\u003c\/li\u003e\n\u003cli\u003eInsider Ownership: $\\mathbf{3.70\\%}$\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; if the model proves cost-effective and reliable, it offers a structural advantage over peers reliant on third parties. The company is developing product candidates such as Probudur™, which in pre-clinical trials showed pain control for $\\text{96}$ hours.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVirpax Pharmaceuticals, Inc. (VRPX) - VRIO Analysis: Focus on Non-Addictive Pain and CNS Disorders\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAligns the company with major unmet medical needs and favorable regulatory\/payer tailwinds favoring non-opioid alternatives.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFlagship product candidate Probudur™ is designed for sustained release local anesthetic effect, potentially managing post-operative pain for up to \u003cstrong\u003e96 hours\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProduct pipeline targets non-addictive pain management, including Envelta (intranasal molecular envelope enkephalin for acute\/chronic pain) and NobrXiol (nasal delivery of pharmaceutical-grade cannabidiol for rare pediatric epilepsy).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow; many biotechs target pain, but Virpax Pharmaceuticals' specific focus on non-addictive solutions is a clear strategic choice.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company is a preclinical-stage biopharmaceutical company focused on branded, non-addictive pain management products.\u003c\/li\u003e\n\u003cli\u003eThe firm utilizes novel and proprietary drug delivery systems across various pain indications.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEasy; competitors can pivot their focus, but replicating the entire pipeline around this theme is harder.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's portfolio includes multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol.\u003c\/li\u003e\n\u003cli\u003eKey technology components include proprietary liposomal encapsulation (Probudur) and Molecular Envelope Technology (MET), which is key to Envelta and NobrXiol.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; this focus defines their entire R\u0026amp;D strategy and resource allocation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProceeds from the January 2025 offering were intended to fund ongoing development activities for commencing clinical trial for Probudur, marketing, and working capital.\u003c\/li\u003e\n\u003cli\u003eThe company employed 2 full-time employees as of a recent report.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; the market focus is clear, but sustained advantage comes only from having the best non-addictive product.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's Common Stock trades on the OTC Markets under the ticker VRPX.\u003c\/li\u003e\n\u003cli\u003eFollowing a 1-for-25 reverse stock split in March 2025, outstanding shares were reduced to approximately 1,242,504.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Sensitivity Analysis on $\\text{\\$6.0}$ Million Raise vs. TTM Loss Burn\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModeling cash burn based on the specified $\\text{12,067}$ Thousand USD Trailing Twelve Months (TTM) loss rate, assuming the $\\text{\\$6.0}$ million raise on January 30, 2025, is the starting cash balance.\u003c\/p\u003e\n\u003cp\u003eThe implied monthly burn rate from the TTM loss is $\\text{12,067}$ Thousand USD \/ $\\text{12}$ months $\\approx$ $\\text{1,005.58}$ Thousand USD per month.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime Horizon (Months)\u003c\/td\u003e\n\u003ctd\u003eAssumed Monthly Burn (Thousand USD)\u003c\/td\u003e\n\u003ctd\u003eCumulative Burn (Thousand USD)\u003c\/td\u003e\n\u003ctd\u003eRemaining Cash from $\\text{\\$6.0M}$ Raise (Thousand USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{1,005.58}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{3,016.74}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{2,983.26}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{1,005.58}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{6,033.48}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$-\\text{33.48}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{1,005.58}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$\\text{9,050.22}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$-\\text{3,050.22}$\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe TTM Net Income was reported as $-\\text{12.07}$M as of December 3, 2025, and the TTM EPS was $-\\text{70.91}$.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516278038677,"sku":"vrpx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vrpx-vrio-analysis.png?v=1740229624","url":"https:\/\/dcf-model.com\/es\/products\/vrpx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}